Pennsylvania Governor Welcomes Federal Marijuana Rescheduling as Catalyst for State Legalization

Pennsylvania Governor Josh Shapiro has praised the Trump administration’s recent decision to reclassify medical marijuana to Schedule III, calling it an 'important step' that bolsters his push for full cannabis legalization in the state. The federal move, announced by Acting U.S. Attorney General Todd Blanche, shifts both FDA-approved cannabis products and state-regulated medical marijuana from the highly restrictive Schedule I to the less stringent Schedule III category under the Controlled Substances Act. This reclassification acknowledges the medical utility of cannabis and delivers significant tax relief to cannabis businesses, though it stops short of legalizing marijuana at the federal level

Governor Shapiro’s administration has emphasized that Pennsylvania is falling behind its neighbors, most of whom have legalized marijuana and are reaping substantial economic benefits. 'Practically every one of our neighbors has legalized marijuana and is benefiting from hundreds of millions of dollars in economic activity and revenue,' Shapiro spokesperson Rosie Lapowsky said. She added, 'This important step by the federal government only adds support to the Governor’s proposal,' reiterating the administration’s readiness to work with state lawmakers to advance legalization and make Pennsylvania 'more competitive and more just.'

The move to Schedule III marks a historic reversal in federal cannabis policy, as marijuana has been classified as a Schedule I substance since 1970, a category reserved for drugs with no accepted medical use and high abuse potential. According to NORML’s Deputy Director Paul Armentano, 'Today’s order marks a historical reversal in federal cannabis policy. It validates the experiences of tens of millions of Americans who have long recognized that cannabis possesses legitimate medical utility.' NORML and other reform advocates have lauded the decision, while opponents, including the Pennsylvania Family Institute, warn of potential public health risks and criticize the decision as a boon for the 'addiction-for-profit industry.'

Political leaders in Pennsylvania remain divided on the issue. While U.S. Senator John Fetterman has long championed marijuana legalization—his office called the federal move 'a good step forward'—Republican Senator Dave McCormick has previously voiced opposition to rescheduling, arguing it could undermine economic and public safety priorities. Pennsylvania Treasurer Stacy Garrity, a Republican gubernatorial hopeful, has yet to take a firm stance but cautioned against overestimating potential tax revenues from legalization. Despite these divisions, public opinion is increasingly in favor of reform: a recent Susquehanna Polling and Research survey found broad support across party lines, with 72% of Democrats, 67% of Republicans, and 64% of independents backing recreational legalization

Pennsylvania first legalized medical marijuana in 2016 and Governor Shapiro has advocated for adult-use legalization since his time as state attorney general. His current budget proposals estimate that recreational cannabis could generate up to $729 million in annual tax revenue if enacted by July 1. However, marijuana not sold through a state medical program or FDA-approved channels remains classified as Schedule I under the new federal guidelines. With 40 states now permitting medical marijuana and 24 plus Washington, D.C. allowing adult use, Pennsylvania faces mounting pressure to align its laws with evolving national trends

From the OG Lab newsroom perspective, this shift in federal policy is a significant turning point for Pennsylvania’s cannabis landscape and could accelerate legislative momentum toward full legalization. As neighboring states capitalize on new revenue streams and public support continues to climb, all eyes are on Harrisburg to see whether lawmakers will seize this opportunity to modernize state cannabis laws and boost economic competitiveness. For industry stakeholders and advocates, the next legislative session will be pivotal in determining Pennsylvania’s place in the national cannabis market